{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T05:28:17Z","timestamp":1774330097190,"version":"3.50.1"},"reference-count":29,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2016,1,6]],"date-time":"2016-01-06T00:00:00Z","timestamp":1452038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Aims: To systemically investigate the in vitro and in vivo antibacterial properties of tebipenem pivoxil tablet. In addition, acute toxicity of this preparation was also studied. Methods: In vitro, minimum inhibitory concentration (MIC) or minimal inhibitory concentration (MBC) were determined by using the serial 2-fold broth or agar dilution methods. Further, cumulative MIC inhibition curves were then made to assess the antibacterial effects of the drug at various concentrations. In vivo, minimum lethal dose (MLD) in combination with maximum tolerance dose (MTD) was used to measure the acute toxicity of the tebipenem pivoxil tablet in mice. After that, sepsis mouse models challenged with Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, and Klebsiella pneumoniae, respectively, were established to evaluate the anti-infective effect of this preparation. Results: The MIC90 values of tebipenem pivoxil against Gram-positive bacteria such as methicillin-sensitive Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA), methicillin-sensitive Staphylococcus epidermidis (MSSE), methicillin-resistant Staphylococcus epidermidis (MRSE), Pyogenic streptococcus, and Enterococcus faecalis were \u22640.125, 16, 0.5, 8, \u22640.125, and 32 \u03bcg\/mL, respectively. Correspondingly, the MIC90 values of tebipenem pivoxil against Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Haemophilus influenzae, Pseudomonas aeruginosa, and Acinetobacter baumannii were 1, 0.5, \u22640.125, 0.25, 64, 64 \u03bcg\/mL, respectively. The MBC values of tebipenem pivoxil against Escherichia coli, Staphylococcus aureus, Klebsiella pneumoniae were 0.016\u20132, 0.063\u201332, 0.031\u201332 \u03bcg\/mL, respectively. The acute toxicity study showed that the MLD of the tebipenem pivoxil tablet was 4.00  g\/kg and the MTD was 3.40  g\/kg in mice. In all the sepsis mouse models, the simultaneous administration of the tebipenem pivoxil tablets significantly reduced mortality of the sepsis-model mice as compared with the control. Furthermore, the survival rate in the tebipenem pivoxil tablet group was remarkably higher than that in the meropenem group in all the sepsis mouse models tested. In the sepsis model challenged with Staphylococcus aureus ATCC29213, Escherichia coli ATCC25922, Pseudomonas aeruginosa ATCC27853, and Pseudomonas aeruginosa clinical strain, respectively, tebipenem pivoxil tablet (100 mg\/kg) displayed a better protective effect than tebipenem pivoxil granules (100 mg\/kg). Conclusions: In summary, tebipenem pivoxil displays an excellent antibacterial activity against a variety of pathogenic bacteria in vitro. Importantly, tebipenem pivoxil tablet significantly protects the sepsis mice challenged with various pathogenic bacteria, which may provide a potential approach to treating bacterial sepsis in clinic.<\/jats:p>","DOI":"10.3390\/molecules21010062","type":"journal-article","created":{"date-parts":[[2016,1,6]],"date-time":"2016-01-06T10:05:59Z","timestamp":1452074759000},"page":"62","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Antibacterial Properties of Tebipenem Pivoxil Tablet, a New Oral Carbapenem Preparation against a Variety of Pathogenic Bacteria in Vitro and in Vivo"],"prefix":"10.3390","volume":"21","author":[{"given":"Qi","family":"Yao","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Yunnan Institute of Materia Medica, Kunming 650111, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingkun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of GLP, Yunnan Institute of Materia Medica, Kunming 650111, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Scientific Management, Yunnan Institute of Materia Medica, Kunming 650111, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Chemical Pharmaceutics, Yunnan Institute of Materia Medica, Kunming 650111, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Yunnan Institute of Materia Medica, Kunming 650111, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peiyue","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Chemical Pharmaceutics, Yunnan Institute of Materia Medica, Kunming 650111, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Yunnan Institute of Materia Medica, Kunming 650111, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zhan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Yunnan Institute of Materia Medica, Kunming 650111, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongbo","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of GLP, Yunnan Institute of Materia Medica, Kunming 650111, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2016,1,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"564","DOI":"10.2174\/092986709787458498","article-title":"Current status of newer carbapenems","volume":"16","author":"Bassetti","year":"2009","journal-title":"Curr. Med. Chem."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.2174\/156802610793176639","article-title":"Current status of carbapenem antibiotics","volume":"10","author":"Oh","year":"2010","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s10156-012-0513-5","article-title":"Good transfer of tebipenem into middle ear effusion conduces to the favorable clinical outcomes of tebipenem pivoxil in pediatric patients with acute otitis media","volume":"19","author":"Sugita","year":"2013","journal-title":"J. Infect. Chemother."},{"key":"ref_4","first-page":"143","article-title":"Pharmacokinetics analysis of tebipenem pivoxil in a phase II clinical trial in otolaryngological infections","volume":"62","author":"Kijima","year":"2009","journal-title":"Jpn. J. Antibiot."},{"key":"ref_5","first-page":"157","article-title":"Effect of new oral antimicrobial agents in outpatient treatment of pneumonia in children","volume":"67","author":"Ouchi","year":"2014","journal-title":"Jpn. J. Antibiot."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/108155890405200740","article-title":"Clinical experience with drotrecogin alfa in treating gram-positive and -negative pathogens in patients with severe sepsis","volume":"52","author":"Cone","year":"2004","journal-title":"J. Investig. Med."},{"key":"ref_7","first-page":"171","article-title":"Clinical efficacy of tebipenem pivoxil treatment in children with pneumonia, who had no relief despite having administered oral beta-lactam antibiotics","volume":"64","author":"Sakata","year":"2011","journal-title":"Jpn. J. Antibiot."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s10156-010-0053-9","article-title":"Investigation of pneumonia-causing pathogenic organisms in children and the usefulness of tebipenem pivoxil for their treatment","volume":"16","author":"Kuroki","year":"2010","journal-title":"J. Infect. Chemother."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2133\/dmpk.23.434","article-title":"Population pharmacokinetics of tebipenem pivoxil (ME1211), a novel oral carbapenem antibiotic, in pediatric patients with otolaryngological infection or pneumonia","volume":"23","author":"Sato","year":"2008","journal-title":"Drug Metab. Pharmacokinet."},{"key":"ref_10","first-page":"155","article-title":"Clinical efficacy, safety and PK-PD analysis of tebipenem pivoxil in a phase II clinical trial in otolaryngological infections","volume":"62","author":"Baba","year":"2009","journal-title":"Jpn. J. Antibiot."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/jac\/dkr437","article-title":"MRSA: The first half century","volume":"67","author":"Moellering","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1139\/W09-109","article-title":"Methicillin-resistant Staphylococcus aureus in Canada: A historical perspective and lessons learned","volume":"56","author":"Cimolai","year":"2010","journal-title":"Can. J. Microbiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"855","DOI":"10.47102\/annals-acadmedsg.V37N10p855","article-title":"Methicillin-resistant Staphylococcus aureus control at the National University Hospital, Singapore: A historical perspective","volume":"37","author":"Tambyah","year":"2008","journal-title":"Ann. Acad. Med. Singap."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1017\/S0950268814001423","article-title":"Epidemiological survey of the first case of vancomycin-resistant Staphylococcus aureus infection in Europe","volume":"143","author":"Resina","year":"2015","journal-title":"Epidemiol. Infect."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1128\/JCM.02187-13","article-title":"Report of the 13th vancomycin-resistant Staphylococcus aureus isolate from the United States","volume":"52","author":"Limbago","year":"2014","journal-title":"J. Clin. Microbiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1172\/JCI68834","article-title":"Mechanisms of vancomycin resistance in Staphylococcus aureus","volume":"124","author":"Gardete","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.mimet.2015.11.011","article-title":"Three supplementary methods for analyzing cytotoxicity of Escherichia coli O157:H7","volume":"120","author":"Zhang","year":"2016","journal-title":"J. Microbiol. Methods"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"618752","DOI":"10.1155\/2015\/618752","article-title":"Comparison of Antibiotic Resistance and Virulence Factors among Escherichia coli Isolated from Conventional and Free-Range Poultry","volume":"2015","author":"Koga","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"ref_19","first-page":"1259","article-title":"In vitro and in vivo activity of tebipenem against ESBL-producing E. coli","volume":"97","author":"Thamlikitkul","year":"2014","journal-title":"J. Med. Assoc. Thail."},{"key":"ref_20","first-page":"116","article-title":"Antimicrobial activity of tebipenem against various clinical isolates from various specimen, mainly urinary tract","volume":"62","author":"Muratani","year":"2009","journal-title":"Jpn. J. Antibiot."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1186\/cc13910","article-title":"Quantification of IgM molecular response by droplet digital PCR as a potential tool for the early diagnosis of sepsis","volume":"18","author":"Tamayo","year":"2014","journal-title":"Crit. Care"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1128\/AAC.01066-05","article-title":"The antimalarial artemisinin synergizes with antibiotics to protect against lethal live Escherichia coli challenge by decreasing proinflammatory cytokine release","volume":"50","author":"Wang","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_23","first-page":"3","article-title":"Evidence for antibiotic-mediated endotoxin release as a contributing factor to lethality in experimental gram-negative sepsis","volume":"101","author":"Morrison","year":"1996","journal-title":"Scand. J. Infect. Dis. Suppl."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.intimp.2003.12.006","article-title":"Chloroquine protects mice from challenge with CpG ODN and LPS by decreasing proinflammatory cytokine release","volume":"4","author":"Hong","year":"2004","journal-title":"Int. Immunopharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1002\/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO;2-U","article-title":"Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments","volume":"32","author":"Rutz","year":"2002","journal-title":"Eur. J. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0167-4889(01)00182-3","article-title":"Toll-like receptors as adjuvant receptors","volume":"1589","author":"Kaisho","year":"2002","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_27","first-page":"E728","article-title":"Sepsis-induced cascade of cytokine mRNA expression: Correlation with metabolic changes","volume":"262","author":"Byerley","year":"1992","journal-title":"Am. J. Physiol."},{"key":"ref_28","first-page":"214","article-title":"Pharmacokinetics of tebipenem pivoxil, a novel oral carbapenem antibiotic, in experimental animals","volume":"62","author":"Kijima","year":"2009","journal-title":"Jpn. J. Antibiot."},{"key":"ref_29","first-page":"127","article-title":"Tissue and aural discharge distribution of tebipenem pivoxil","volume":"62","author":"Baba","year":"2009","journal-title":"Jpn. J. Antibiot."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/21\/1\/62\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T19:17:22Z","timestamp":1760210242000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/21\/1\/62"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,6]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,1]]}},"alternative-id":["molecules21010062"],"URL":"https:\/\/doi.org\/10.3390\/molecules21010062","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,6]]}}}